Phone App Tracks Side Effects in People with Melanoma on Immune Therapy

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with skin cancer or melanoma who are starting treatment with two immune therapy drugs, ipilimumab and nivolumab. It tests a mobile app for tracking symptoms.

Age

18 years or older

Sex

Men and women can join.

Disease stage

Any skin cancer or melanoma.

Earlier treatment

People must be starting dual immune checkpoint inhibitor therapy (ipilimumab/nivolumab).

Main reasons for not taking part

• People who do not meet the inclusion criteria cannot join.

The registry criteria, word for word

What the trial wants to find out

This study is being done to better understand patient experiences with using a mobile application, known as Vigilant, to monitor symptoms as outpatients and to gather preliminary data on the potential clinical benefit to remote monitoring of adverse events.

The group in the trial

• Observational

  Patients undergo standard of care treatment with ipilimumab/nivolumab and answer questions and enter symptoms in the mobile Vigilant application. Patients wearing a compatible watch have their vital signs recorded at the same time symptoms are being entered. Based on the severity of symptoms, patients may be recommended to reach out to their healthcare team or to go to the emergency room. Additionally, patients complete a survey and may have their medical charts reviewed on study.

  Treatment: Non-Interventional Study